Needham & Company LLC restated their hold rating on shares of Gilead Sciences (NASDAQ:GILD – Free Report) in a research report sent to investors on Wednesday,Benzinga reports. Other analysts also ...

Shares of Gilead Sciences ( GILD -1.77%) were jumping 7.9% higher on Wednesday at 11:34 a.m. The solid gain came after the ...

Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) will be announcing earnings results tomorrow afternoon. Here’s what to expect. Gilead Sciences beat analysts’ revenue expectations by 7. ...

Maxim Group analyst Michael Okunewitch maintained a Hold rating on Gilead Sciences (GILD – Research Report) today. The company’s shares closed ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Gilead Sciences (GILD – Research Report) and ...

In the latest market close, Gilead Sciences (GILD) reached $98.38, with a +1.21% movement compared to the previous day. The stock outpaced the S&P 500's daily loss of 0.76%. Elsewhere, the Dow saw ...

What Happened? Shares of biopharmaceutical company Gilead Sciences (NASDAQ:GILD) jumped 8.6% in the morning session after the ...

Investors with a lot of money to spend have taken a bullish stance on Gilead Sciences GILD. And retail traders should know. We noticed this today when the trades showed up on publicly available ...

Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) – Zacks Research boosted their Q2 2025 earnings per share estimates for Gilead Sciences in a report issued on Thursday, January 16th.